Paricalcitol: a review of its use in the management of secondary hyperparathyroidism.

Article Details

Citation

Copy to clipboard

Robinson DM, Scott LJ

Paricalcitol: a review of its use in the management of secondary hyperparathyroidism.

Drugs. 2005;65(4):559-76.

PubMed ID

15733015 [ View in PubMed

]

Abstract

Paricalcitol (Zemplar) is a synthetic vitamin D(2) analogue that inhibits the secretion of parathyroid hormone (PTH) through binding to the vitamin D receptor. It is approved in the US and in most European nations for intravenous use in the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure in adult, and in the US paediatric, patients. Paricalcitol effectively reduced elevated serum PTH levels and was generally well tolerated in children and adults with secondary hyperparathyroidism associated with chronic renal failure. In well designed clinical trials, paricalcitol was as effective as calcitriol and as well tolerated in terms of the incidence of prolonged hypercalcaemia and/or elevated calcium-phosphorus product (Ca x P). Thus, paricalcitol is a useful option for the management of secondary hyperparathyroidism in adults and children with chronic renal failure.

DrugBank Data that Cites this Article

Drug Enzymes

Drug	Enzyme	Kind	Organism	Pharmacological Action	Actions
Paricalcitol	1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial	Protein	Humans	Unknown	Substrate	Details